Northern Trust Corp Boosts Holdings in Epizyme, Inc. (EPZM)

Northern Trust Corp raised its holdings in shares of Epizyme, Inc. (NASDAQ:EPZM) by 0.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 504,770 shares of the biopharmaceutical company’s stock after purchasing an additional 100 shares during the period. Northern Trust Corp owned 0.86% of Epizyme worth $7,622,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of EPZM. Vanguard Group Inc. increased its position in Epizyme by 4.5% during the 1st quarter. Vanguard Group Inc. now owns 3,218,862 shares of the biopharmaceutical company’s stock valued at $55,202,000 after purchasing an additional 139,066 shares during the period. Renaissance Technologies LLC purchased a new position in Epizyme during the 1st quarter valued at about $1,975,000. Federated Investors Inc. PA increased its position in Epizyme by 477.6% during the 2nd quarter. Federated Investors Inc. PA now owns 89,505 shares of the biopharmaceutical company’s stock valued at $1,352,000 after purchasing an additional 74,009 shares during the period. TIAA CREF Investment Management LLC increased its position in Epizyme by 37.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 148,487 shares of the biopharmaceutical company’s stock valued at $2,242,000 after purchasing an additional 40,535 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in Epizyme by 25.3% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 161,646 shares of the biopharmaceutical company’s stock valued at $2,773,000 after purchasing an additional 32,650 shares during the period. 72.20% of the stock is currently owned by institutional investors and hedge funds.

Epizyme, Inc. (NASDAQ:EPZM) opened at $14.25 on Friday. Epizyme, Inc. has a 12-month low of $9.30 and a 12-month high of $20.45.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. equities analysts predict that Epizyme, Inc. will post -2.23 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/11/northern-trust-corp-boosts-holdings-in-epizyme-inc-epzm.html.

In related news, Director David M. Mott bought 200,000 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was bought at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the purchase, the director now directly owns 6,000 shares of the company’s stock, valued at $91,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total transaction of $246,600.00. Following the completion of the sale, the insider now owns 23,123 shares of the company’s stock, valued at $380,142.12. The disclosure for this sale can be found here. Insiders sold a total of 45,000 shares of company stock valued at $733,950 over the last quarter. 25.20% of the stock is owned by company insiders.

A number of research analysts have commented on EPZM shares. BidaskClub raised shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. ValuEngine downgraded shares of Epizyme from a “hold” rating to a “sell” rating in a research report on Monday, November 6th. Royal Bank Of Canada reissued a “buy” rating and set a $20.00 target price on shares of Epizyme in a research report on Friday, September 15th. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. Finally, Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $22.67.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply